<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02401269</url>
  </required_header>
  <id_info>
    <org_study_id>PRO14040373</org_study_id>
    <nct_id>NCT02401269</nct_id>
  </id_info>
  <brief_title>Cardiovascular Risk in HIV Patients on Antiretroviral Therapy Therapy: The MHEART Study</brief_title>
  <acronym>MHEART</acronym>
  <official_title>Cardiovascular Risk in HIV Patients on Antiretroviral Therapy Therapy: The MHEART Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fogarty International Center of the National Institute of Health</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CVD accounts for 15% of all deaths in Malawi. Both HIV and ART are risk factors for CVD&#xD;
      through direct toxic and inflammatory cardiovascular effects. (44,45). At the moment, one out&#xD;
      of every 10 Malawian is HIV positive and roughly 8 out of 10 of those infected are now on ART&#xD;
      (2). Therefore, HIV and ART may be contributing to the burden of CVD in Malawi. Currently,&#xD;
      there are only a few studies assessing CVD risk in the HIV patient population on ART. In&#xD;
      Malawi, no such studies exist. Therefore, the investigators propose a novel study assessing&#xD;
      baseline cardiovascular disease risk using two novel ultrasound technologies in HIV patients&#xD;
      on ART. Cardiovascular disease risk will be assessed using surrogate cardiovascular markers&#xD;
      of disease. These surrogates include markers of endothelial function and cardiovascular&#xD;
      modulating inflammatory biomarkers. The inflammatory biomarkers measured will be TNF-alpha,&#xD;
      IL-6, and CRP. Aspirin, by way of its antiplatelet and anti-inflammatory effect has been&#xD;
      demonstrated to inhibit atherosclerosis by way of decreasing TNF-alpha, IL-6, CRP and&#xD;
      improving endothelial function. Therefore a second aim of the study will be to demonstrate&#xD;
      that aspirin improves surrogate markers of atherosclerosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To address our objectives we have designed a six-month prospective randomized controlled&#xD;
      study (RCT) investigating cardiovascular disease risk in HIV patients on ART with the&#xD;
      implementation of an aspirin versus placebo strategy to investigate whether this risk can be&#xD;
      modified. As nearly all HIV patients are anticipated to be on ART in the upcoming decade, we&#xD;
      have decided to open this study to only virally suppressed HIV on ART. A total of 100 virally&#xD;
      suppressed HIV positive Malawians on ART will be enrolled in this study. Initial screening&#xD;
      will occur in the patient population identified as being HIV positive with viral load&#xD;
      suppression on ART in the last 3 months. The initial screening will provide cross-sectional&#xD;
      information on baseline demographic, clinical, and laboratory characteristics of virally&#xD;
      suppressed HIV patients on ART and will assess baseline cardiovascular risk using laboratory&#xD;
      biomarker data and endothelial function as surrogate markers (see section under procedures).&#xD;
      Ability of distal arteries to dilate under stress will be measured using novel ultrasound&#xD;
      technologies applicable to the limited resource healthcare settings in Malawi. After initial&#xD;
      screening, eligibility into the study will be determined and selected participants will be&#xD;
      randomized into one of two arms:&#xD;
&#xD;
        1. Oral aspirin 325mg daily&#xD;
&#xD;
        2. Oral placebo daily.&#xD;
&#xD;
      This longitudinal RCT will reassess cardiovascular risk at the one-month, 3-month, and&#xD;
      six-month mark using the same CVD surrogate measurements of atherosclerosis performed during&#xD;
      the initial screening.&#xD;
&#xD;
      Procedures assessing surrogate CVD markers for atherosclerosis:&#xD;
&#xD;
        1. Laboratory analysis (Venipuncture): Inflammatory biomarkers&#xD;
&#xD;
           â€¢ C-Reactive Protein (CRP), Interleukin-6, Tumor Necrosis Factor- alpha&#xD;
&#xD;
        2. Endo-PAT analysis&#xD;
&#xD;
        3. Brachial Flow Mediated dilation&#xD;
&#xD;
        4. Carotid Intima-Media Thickness&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reactive Hyperemia Index</measure>
    <time_frame>Baseline, 30 days after treatment, 60 days after treatment, 90 days after treatment</time_frame>
    <description>Assessment of peripheral arterial endothelial function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of inflammatory biomarkers- TNF-alpha, C-Reactive Protein, Interleukin-6</measure>
    <time_frame>Baseline, 30 days after treatment, 60 days after treatment, 90 days after treatment.</time_frame>
    <description>Assessment of biochemical surrogates of cardiovascular disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>30 days, 60 days, 90 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Cardiovascular Disease Risk in HIV Patients</condition>
  <condition>Endothelial Function</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin 325mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Malawian men and women ages 18-70 who are HIV positive and on ART for at least 6 months on&#xD;
        standard therapy (1st line, 2nd line or 3rd line). The HIV viral load at time of enrollment&#xD;
        must be suppressed confirmed by HIV DNA PCR in the last 60 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All patients with risk factors that result in endothelial dysfunction and atherosclerosis&#xD;
        will be excluded based on the following exclusion criteria. The rationale behind this is to&#xD;
        isolate the effects of virally suppressed HIV on endothelial activity.&#xD;
&#xD;
          1. Presence of HIV viral load in the last 60 days&#xD;
&#xD;
          2. History of diagnosed Diabetes Mellitus&#xD;
&#xD;
          3. Fasting blood sugar &gt;110 at time of enrollment determined by glucose on chemistry&#xD;
             profile&#xD;
&#xD;
          4. Uncontrolled Hypertension defined as systolic blood pressure &gt; or equal to 140 and or&#xD;
             diastolic &gt;100 mmHg at time of enrollment&#xD;
&#xD;
          5. AST or ALT &gt;200 within the last 30 days. If not obtained in this interval, a baseline&#xD;
             AST/ALT will be obtained&#xD;
&#xD;
          6. Renal Failure at time of recruitment (Gfr. &lt;60ml/min/1.73) based on Cockcroft Gault&#xD;
             equation.&#xD;
&#xD;
          7. History of myocardial infarction, peripheral vascular disease, cerebrovascular&#xD;
             disease. These will also be assessed clinically at the time of enrollment&#xD;
&#xD;
          8. Health condition that would place patient at a health risk for perfusion ischemia&#xD;
             during EndoPAT, FMD, CIMT measurement.&#xD;
&#xD;
          9. Current tobacco use or history of tobacco use in the last 90 days&#xD;
&#xD;
         10. Platelet count less than 100 at time of enrollment&#xD;
&#xD;
         11. History of active brain mass/lesion&#xD;
&#xD;
         12. Gastrointestinal bleeding in last 12 months&#xD;
&#xD;
         13. History of hemorrhagic stroke&#xD;
&#xD;
         14. Major life threatening bleeding in the last 12 months&#xD;
&#xD;
         15. Patients considered to be a high bleed risk based on physician assessment&#xD;
&#xD;
         16. History of medication noncompliance in last 3 months&#xD;
&#xD;
         17. Pregnancy&#xD;
&#xD;
         18. Contraindications to aspirin&#xD;
&#xD;
               -  Previous allergic reaction to aspirin or similar medications to aspirin&#xD;
&#xD;
               -  Asthma with nasal congestion or nasal polyps&#xD;
&#xD;
               -  Bleeding disorders (inherited or acquired)&#xD;
&#xD;
               -  Chicken pox&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anil Purohit, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lighthouse Trust</name>
      <address>
        <city>Lilongwe</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malawi</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>March 24, 2015</study_first_submitted>
  <study_first_submitted_qc>March 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <last_update_submitted>January 13, 2016</last_update_submitted>
  <last_update_submitted_qc>January 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Anil Purohit, MD</investigator_full_name>
    <investigator_title>Cardiology Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

